Moloney Securities Asset Management LLC Takes Position in Illumina, Inc. (NASDAQ:ILMN)

Moloney Securities Asset Management LLC acquired a new stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,476 shares of the life sciences company's stock, valued at approximately $276,000.

Several other large investors also recently bought and sold shares of ILMN. Diversified Trust Co purchased a new position in shares of Illumina during the first quarter worth about $355,000. State of Alaska Department of Revenue lifted its position in Illumina by 2.5% in the first quarter. State of Alaska Department of Revenue now owns 18,527 shares of the life sciences company's stock valued at $1,469,000 after purchasing an additional 445 shares during the period. Merit Financial Group LLC lifted its position in Illumina by 344.8% in the first quarter. Merit Financial Group LLC now owns 13,036 shares of the life sciences company's stock valued at $1,034,000 after purchasing an additional 10,105 shares during the period. Trexquant Investment LP lifted its position in Illumina by 16.7% in the fourth quarter. Trexquant Investment LP now owns 142,977 shares of the life sciences company's stock valued at $19,106,000 after purchasing an additional 20,506 shares during the period. Finally, Robeco Institutional Asset Management B.V. lifted its position in Illumina by 15.1% in the first quarter. Robeco Institutional Asset Management B.V. now owns 516,293 shares of the life sciences company's stock valued at $40,963,000 after purchasing an additional 67,676 shares during the period. Institutional investors and hedge funds own 89.42% of the company's stock.

Analysts Set New Price Targets

ILMN has been the subject of a number of recent analyst reports. Stephens restated an "overweight" rating and issued a $105.00 price objective on shares of Illumina in a research report on Tuesday, May 20th. Royal Bank Of Canada reduced their price objective on shares of Illumina from $128.00 to $112.00 and set an "outperform" rating for the company in a research report on Tuesday, April 8th. Evercore ISI raised their price objective on shares of Illumina from $116.00 to $128.00 and gave the company an "outperform" rating in a research report on Tuesday. Guggenheim reduced their price objective on shares of Illumina from $122.00 to $114.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Finally, Canaccord Genuity Group lifted their price target on shares of Illumina from $87.00 to $99.00 and gave the company a "hold" rating in a research report on Wednesday, June 11th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Illumina currently has a consensus rating of "Hold" and an average price target of $125.11.

Illumina Price Performance

Shares of ILMN traded down $0.80 during mid-day trading on Friday, reaching $99.25. 1,998,677 shares of the company's stock were exchanged, compared to its average volume of 2,153,999. The company has a quick ratio of 1.48, a current ratio of 1.86 and a debt-to-equity ratio of 0.63. The company has a 50-day simple moving average of $87.18 and a two-hundred day simple moving average of $96.21. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $156.66. The company has a market cap of $15.71 billion, a price-to-earnings ratio of -16.35, a PEG ratio of 1.95 and a beta of 1.36.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The life sciences company reported $0.97 earnings per share for the quarter, topping analysts' consensus estimates of $0.96 by $0.01. Illumina had a negative net margin of 22.25% and a positive return on equity of 25.54%. The business had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.03 billion. During the same period last year, the company posted $0.98 EPS. The company's revenue was down 1.4% on a year-over-year basis. On average, sell-side analysts predict that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Ankur Dhingra bought 6,100 shares of the stock in a transaction on Monday, May 12th. The stock was purchased at an average cost of $81.21 per share, with a total value of $495,381.00. Following the purchase, the chief financial officer owned 24,906 shares of the company's stock, valued at approximately $2,022,616.26. The trade was a 32.44% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Insiders own 2.60% of the company's stock.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.